

From: [Director_PTABDecision_Review](#)
To: [Yung-Hoon \(Sam\) Ha](#); [Bridget Belcher](#); [Raymond Habbaz](#); [Sun Pharma IPR Service](#); [Megan Hart](#); [Brian Larivee](#); [Chad Landmon](#); [Corey Casey](#); [Kendall Gurule](#); [James Murphy](#)
Cc: [Trials](#)
Subject: RE: IPR2024-01312
Date: Friday, March 20, 2026 3:41:00 PM

Counsel,

Patent Owner's request for authorization to submit seven exhibits with its request for Director Review in the above identified proceeding is granted.

Thanks.

IPR2024-01312
Ex. 3100

From: Yung-Hoon (Sam) Ha <YHa@desmaraisllp.com>
Sent: Wednesday, March 18, 2026 9:04 PM
To: Director_PTABDecision_Review <Director_PTABDecision_Review@uspto.gov>; Trials <Trials@USPTO.GOV>
Cc: Bridget Belcher <BBelcher@desmaraisllp.com>; Yung-Hoon (Sam) Ha <YHa@desmaraisllp.com>; Raymond Habbaz <RHabbaz@desmaraisllp.com>; Sun Pharma IPR Service <SunPharmaIPRService@desmaraisllp.com>; Megan Hart <mkhart@polsinelli.com>; Brian Larivee <blarivee@polsinelli.com>; Chad Landmon <clandmon@polsinelli.com>; Corey Casey <CCasey@Polsinelli.com>; Kendall Gurule <kgurule@polsinelli.com>; James Murphy <jpmurphy@polsinelli.com>
Subject: IPR2024-01312

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Dear Honorable Director/Board,

In light of the parties obligation to keep the Board apprised of the ITC matter and as part of Patent Owner's Director Review Request that is currently due on March 25, 2026, Patent Owner requests authorization to submit the following documents as exhibits. Petitioner does not oppose the submission of documents #1-#3 but does oppose the submission of documents #4-7 for the reasons provided below.

1. "Notice Of A Commission Determination Requesting Additional Briefing From The Parties; Extension Of The Target Date" dated March 5, 2026
2. "Complainant Sun Pharmaceutical Industries, Inc.'s Submission In Response To Commission's Notice Requesting Additional Briefing" dated March 12, 2026 and Complainant's responsive briefing on this issue to be filed by March 19, 2026
"Respondent Biofrontera Inc., Biofrontera Pharma GmbH, Biofrontera Bioscience

3.

GmbH, and Biofrontera AG's Response To The Commission's Request For Additional Briefing" dated March 12, 2026 and Respondent's responsive briefing on this issue to be filed by March 19, 2026

4. "Respondent Biofrontera Inc., Biofrontera Pharma GmbH, Biofrontera Bioscience GmbH, and Biofrontera AG's Petition For Review Of The Initial Determination Finding Violation Of Section 337," dated November 17, 2025
5. "Respondent Biofrontera AG, Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera Inc.'s Pre-Hearing Brief" dated May 23, 2025
6. "Respondent Biofrontera AG, Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera Inc.'s Post-Hearing Brief" dated July 21, 2025
7. "Respondent Biofrontera AG, Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera Inc. Responsive Post-Hearing Brief" dated August 4, 2025

Each of the documents itemized in #4-#7 above are cited in the Parties' Responses to the Commission's Notice Requesting Additional Briefing (itemized in #2 and #3 above) and Patent Owner believes the documents will provide a more fulsome record for the Director.

Petitioner opposes the submission of documents #4-#7 since the parties have already submitted voluminous exhibits from the ITC proceeding and provided supplemental briefs to the PTAB regarding the ITC matter shortly before the oral hearing took place. These documents were available to submit before the oral hearing and it is the Petitioner's position that request for submission of documents #4-#7 are untimely attempts to raise new arguments.

Yung-Hoon (Sam) Ha | Partner

Desmarais LLP

230 Park Avenue

New York, NY 10169

T: (212) 351-3411 | E: yha@desmaraisllp.com

This email may contain confidential and privileged material for the use of the intended recipient. Any review, use, or distribution by anyone other than the addressee is strictly prohibited. If you are not the intended recipient, please contact the sender by reply email and delete all copies of this message.